Biomarkers /
HER2
Back to Biomarkers List
Overview
Biomarker-Directed Therapies
HER2 is a predictive biomarker for use of trastuzumab, fulvestrant, aromatase inhibitor, lapatinib, pertuzumab, everolimus, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan, abemaciclib, capecitabine, endocrine therapy, alpelisib, cisplatin, docetaxel, exemestane, letrozole, paclitaxel, palbociclib, pembrolizumab, ribociclib, anastrozole, atezolizumab, carboplatin, fluorouracil, ivosidenib, margetuximab, nab-paclitaxel, neratinib, pertuzumab/trastuzumab/hyaluronidase, sacituzumab govitecan, tamoxifen, trastuzumab/hyaluronidase, and tucatinib in patients.
Breast carcinoma, adenocarcinoma of the gastroesophageal junction, colorectal carcinoma, gastric carcinoma, and malignant salivary gland neoplasm have the most therapies with HER2 as a predictive biomarker.
Of the therapies with HER2 as a predictive biomarker, 23 are FDA-approved in at least one clinical setting and 27 have NCCN guidelines in at least one clinical setting.
HER2 Overexpression, HER2 Positive, HER2 Deficient Expression, and HER2 Negative are the top alterations on HER2 targeted by therapies [4].
Abemaciclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. |
Ado-Trastuzumab Emtansine +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated (as a single agent) for the treatment of patients with HER2+ positive breast cancer in either the adjuvant or metastatic setting who previously received trastuzumab and a taxane, separately or in combination. |
Malignant Salivary Gland Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic). |
Everolimus +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
Fam-Trastuzumab Deruxtecan +
Adenocarcinoma Of The Gastroesophageal Junction -
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Approved for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting |
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended as subsequent line therapy. |
Esophageal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended as subsequent line therapy for patients with HER2-positive disease. |
Gastric Adenocarcinoma -
Ivosidenib +
Breast Invasive Lobular Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Sensitive |
| Clinical Setting(s): Metastatic (BNF) |
Lapatinib +
Breast Carcinoma -
Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Neoadjuvant (BNF) |
Margetuximab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated in combination with chemotherapy for metastatic HER2-positive breast cancer that received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. |
Neratinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2-positive breast cancer, both in combination with capecitabine for advanced or metastatic disease with two or more prior anti-HER2 based regimens in the metastatic setting, and as a single agent for extended adjuvant treatment following adjuvant trastuzumab-based therapy. |
Pembrolizumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated in combination with chemotherapy for patients with locally recurrent, unresectable, or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) >= 10]. |
Pertuzumab +
Pertuzumab/trastuzumab/hyaluronidase +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2+ breast cancer, for adjuvant treatment or for metastatic disease. Per NCCN, pertuzumab/trastuzumab/hyaluronidase injection for subcutaneous use may be substituted for trastuzumab + pertuzumab in any regimen. |
Sacituzumab Govitecan +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. |
Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2-overexpressing breast cancer: (1) for metastatic disease with paclitaxel as first-line treatment, and as a single agent after one or more chemotherapy regimens. NCCN recommended with various chemotherapy combinations. (2) for adjuvant treatment with chemotherapy and as a single agent following multi-modality anthracycline based therapy. (3) Also NCCN recommended for neoadjuvant treatment. |
Endometrial Adenocarcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended in combination with carboplatin and paclitaxel for stage III/IV or recurrent, HER2-positive uterine serous carcinoma. |
Gastric Carcinoma -
Malignant Esophageal Neoplasm -
Malignant Salivary Gland Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended as a single agent or in combination with docetaxel for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic). |
Trastuzumab/hyaluronidase +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HER2+ breast cancer, for adjuvant treatment or for metastatic disease. Per NCCN, trastuzumab/hyaluronidase injection for subcutaneous use may be substituted for trastuzumab in any regimen. |
Abemaciclib + Aromatase Inhibitor +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. |
Abemaciclib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Ado-Trastuzumab Emtansine + Endocrine Therapy +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer. |
Alpelisib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: PIK3CA E545Q, PIK3CA Q546K, PIK3CA Q546P, PIK3CA E365K, PIK3CA E453K, PIK3CA G1049R, PIK3CA G106V, PIK3CA G118D, PIK3CA K111E, PIK3CA K111N, PIK3CA M1043I, PIK3CA M1043V, PIK3CA N345K, PIK3CA P447_L455del, PIK3CA P539R, PIK3CA R108H, PIK3CA R88Q, PIK3CA R93W, PIK3CA T1025A, PIK3CA V344G, PIK3CA V344M Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative, PIK3CA-mutated, recurrent or metastatic breast cancer. |
Anastrozole + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as first line therapy. |
Aromatase Inhibitor + Lapatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved with letrozole as the aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. NCCN recommended for any aromatase inhibitor. |
Aromatase Inhibitor + Lapatinib + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positve/HER2-positive recurrent or metastastic breast cancer. |
Aromatase Inhibitor + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved for HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy in postmenopausal women or in men. |
Aromatase Inhibitor + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for pre/perimenopausal or postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. |
Aromatase Inhibitor + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
Atezolizumab + Nab-Paclitaxel +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area. |
Capecitabine + Cisplatin + Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Capecitabine + Lapatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for advanced or metastatic breast cancer that overexpresses HER2 and that had prior therapy including an anthracycline, a taxane, and trastuzumab. |
Capecitabine + Trastuzumab + Tucatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for patients with advanced HER2-positive breast cancer that is unresectable or metastatic, who have received one or more prior treatments. |
Carboplatin + Docetaxel + Trastuzumab +
Cisplatin + Fluorouracil + Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
Docetaxel + Trastuzumab +
Endocrine Therapy + Pertuzumab + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer, with or without chemotherapy. |
Endocrine Therapy + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN), Metastatic (NCCN) | |
| Note: Recommend for HR-positive/HER2-positive breast cancer, with fulvestrant, tamoxifen, or aromatase inhibitor metastastic disease, or with tamoxifen or aromatase inhibitor for adjuvant treatment. |
Everolimus + Exemestane +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with advanced HR+, HER2- breast cancer after failure of treatment with letrozole or anastrozole. |
Everolimus + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as subsequent line therapy. |
Everolimus + Tamoxifen +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as subsequent line therapy. |
Fulvestrant + Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as first line therapy. |
Fulvestrant + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Fulvestrant + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy, or following disease progression on endocrine therapy. |
Lapatinib + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommened for recurrent or metastatic HER2-positive breast cancer, without cytotoxic therapy. |
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended as subsequent line therapy. |
Paclitaxel + Pertuzumab + Trastuzumab +
Paclitaxel + Trastuzumab +
Pembrolizumab + Trastuzumab +
Adenocarcinoma Of The Gastroesophageal Junction -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced, unresectable, or metastatic HER2+ gastric or GEJ adenocarcinoma. |
Gastric Adenocarcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced, unresectable, or metastatic HER2+ gastric or GEJ adenocarcinoma. |
Pertuzumab + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: FDA approved for HER2-positive breast cancer, for metastatic disease with paclitaxel for with no prior anti-HER2 therapy or chemotherapy in that setting, and for adjuvant and neoadjuvant treatment in combination with chemotherapy. Per NCCN, other chemotherapy combinations, or no chemotherapy combination, are options for these settings. |
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must not match any of the following: BRAF V600E, BRAF V600_K601delinsE, KRAS A11_G12dup, KRAS A146S, KRAS A59E, KRAS A59G, KRAS A59P, KRAS A59S, KRAS A59T, KRAS A59V, KRAS Amplification, KRAS D119N, KRAS D33E, KRAS F156L, KRAS F28L, KRAS G10dup, KRAS G12F, KRAS G12L, KRAS G13E, KRAS G60R, KRAS K147E, KRAS K5N, KRAS L19F, KRAS N116S, KRAS P34L, KRAS P34R, KRAS Q22E, KRAS Q22K, KRAS Q22R, KRAS Q61E, KRAS T58I, KRAS T74P, KRAS V14I, KRAS V14L, KRAS Y71H, NRAS A59D, NRAS A59G, NRAS A59P, NRAS A59S, NRAS A59T, NRAS A59V, NRAS G60E |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended as subsequent line therapy. |
Malignant Salivary Gland Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: NCCN recommended for HER2-positive salivary gland tumors (recurrent, unresectable, metastatic). |
Clinical Trials
HER2 status serves as an inclusion eligibility criteria in 1374 clinical trials, of which 969 are open and 405 are closed. Of the trials that contain HER2 status as an inclusion criterion, 25 are early phase 1 (17 open), 383 are phase 1 (247 open), 210 are phase 1/phase 2 (145 open), 534 are phase 2 (383 open), 16 are phase 2/phase 3 (11 open), 164 are phase 3 (134 open), 6 are phase 4 (2 open), and 36 are no phase specified (30 open).
Trials with HER2 status in the inclusion eligibility criteria most commonly target breast carcinoma, invasive breast carcinoma, adenocarcinoma of the gastroesophageal junction, breast adenocarcinoma, and gastric adenocarcinoma [4].
The most frequent alterations to serve as inclusion eligibility criteria are HER2 Deficient Expression, HER2 Negative, HER2 Positive, HER2 Overexpression, and HER2 Equivocal [4].
Trastuzumab, paclitaxel, pembrolizumab, cyclophosphamide, and fulvestrant are the most frequent therapies in trials with HER2 as an inclusion criteria [4].
Significance of HER2 in Diseases
Breast Carcinoma +
HER2 is an inclusion criterion in 1089 clinical trials for breast carcinoma, of which 731 are open and 358 are closed. Of the trials that contain HER2 status and breast carcinoma as inclusion criteria, 18 are early phase 1 (11 open), 314 are phase 1 (190 open), 183 are phase 1/phase 2 (129 open), 414 are phase 2 (278 open), 11 are phase 2/phase 3 (7 open), 119 are phase 3 (94 open), 6 are phase 4 (2 open), and 24 are no phase specified (20 open) [4].
Everolimus, exemestane, ado-trastuzumab emtansine, alpelisib, fulvestrant, aromatase inhibitor, trastuzumab, sacituzumab govitecan, letrozole, palbociclib, ribociclib, lapatinib, margetuximab, neratinib, paclitaxel, pertuzumab, tamoxifen, pembrolizumab, pertuzumab/trastuzumab/hyaluronidase, fam-trastuzumab deruxtecan, abemaciclib, endocrine therapy, anastrozole, atezolizumab, nab-paclitaxel, capecitabine, tucatinib, carboplatin, docetaxel, and trastuzumab/hyaluronidase have evidence of efficacy in patients with HER2 mutation in breast carcinoma [4].
Adenocarcinoma Of The Gastroesophageal Junction +
HER2 is an inclusion criterion in 81 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 59 are open and 22 are closed. Of the trials that contain HER2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 25 are phase 1 (17 open), 16 are phase 1/phase 2 (12 open), 21 are phase 2 (17 open), 4 are phase 2/phase 3 (3 open), 14 are phase 3 (10 open), and 1 is no phase specified (0 open) [4].
Capecitabine, cisplatin, trastuzumab, fluorouracil, fam-trastuzumab deruxtecan, and pembrolizumab have evidence of efficacy in patients with HER2 mutation in adenocarcinoma of the gastroesophageal junction [4].
Colorectal Carcinoma +
HER2 is an inclusion criterion in 72 clinical trials for colorectal carcinoma, of which 48 are open and 24 are closed. Of the trials that contain HER2 status and colorectal carcinoma as inclusion criteria, 42 are phase 1 (26 open), 20 are phase 1/phase 2 (15 open), 9 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].
Fam-trastuzumab deruxtecan, lapatinib, trastuzumab, and pertuzumab have evidence of efficacy in patients with HER2 mutation in colorectal carcinoma [4].
Gastric Carcinoma +
HER2 is an inclusion criterion in 71 clinical trials for gastric carcinoma, of which 40 are open and 31 are closed. Of the trials that contain HER2 status and gastric carcinoma as inclusion criteria, 36 are phase 1 (17 open), 17 are phase 1/phase 2 (13 open), 13 are phase 2 (8 open), 1 is phase 2/phase 3 (0 open), and 4 are phase 3 (2 open) [4].
Capecitabine, cisplatin, trastuzumab, and fluorouracil have evidence of efficacy in patients with HER2 mutation in gastric carcinoma [4].
Gastric Adenocarcinoma +
HER2 is an inclusion criterion in 62 clinical trials for gastric adenocarcinoma, of which 49 are open and 13 are closed. Of the trials that contain HER2 status and gastric adenocarcinoma as inclusion criteria, 17 are phase 1 (13 open), 12 are phase 1/phase 2 (10 open), 18 are phase 2 (14 open), 3 are phase 2/phase 3 (3 open), 11 are phase 3 (9 open), and 1 is no phase specified (0 open) [4].
Fam-trastuzumab deruxtecan, pembrolizumab, and trastuzumab have evidence of efficacy in patients with HER2 mutation in gastric adenocarcinoma [4].
Esophageal Carcinoma +
HER2 is an inclusion criterion in 31 clinical trials for esophageal carcinoma, of which 19 are open and 12 are closed. Of the trials that contain HER2 status and esophageal carcinoma as inclusion criteria, 11 are phase 1 (4 open), 11 are phase 1/phase 2 (9 open), 6 are phase 2 (4 open), 2 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].
Fam-trastuzumab deruxtecan has evidence of efficacy in patients with HER2 mutation in esophageal carcinoma [4].
Breast Invasive Lobular Carcinoma +
HER2 is an inclusion criterion in 5 clinical trials for breast invasive lobular carcinoma, of which 5 are open and 0 are closed. Of the trials that contain HER2 status and breast invasive lobular carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Ivosidenib has evidence of efficacy in patients with HER2 mutation in breast invasive lobular carcinoma [4].
Malignant Salivary Gland Neoplasm +
HER2 is an inclusion criterion in 2 clinical trials for malignant salivary gland neoplasm, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and malignant salivary gland neoplasm as inclusion criteria, 2 are phase 2 (2 open) [4].
Ado-trastuzumab emtansine, pertuzumab, and trastuzumab have evidence of efficacy in patients with HER2 mutation in malignant salivary gland neoplasm [4].
Endometrial Adenocarcinoma +
HER2 is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and endometrial adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Trastuzumab has evidence of efficacy in patients with HER2 mutation in endometrial adenocarcinoma [4].
Malignant Esophageal Neoplasm +
Trastuzumab has evidence of efficacy in patients with HER2 mutation in malignant esophageal neoplasm [4].
Malignant Solid Tumor +
HER2 is an inclusion criterion in 203 clinical trials for malignant solid tumor, of which 138 are open and 65 are closed. Of the trials that contain HER2 status and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 138 are phase 1 (90 open), 50 are phase 1/phase 2 (34 open), and 14 are phase 2 (13 open) [4].
Non-Small Cell Lung Carcinoma +
HER2 is an inclusion criterion in 122 clinical trials for non-small cell lung carcinoma, of which 80 are open and 42 are closed. Of the trials that contain HER2 status and non-small cell lung carcinoma as inclusion criteria, 69 are phase 1 (40 open), 31 are phase 1/phase 2 (22 open), 21 are phase 2 (17 open), and 1 is phase 3 (1 open) [4].
Ovarian Carcinoma +
HER2 is an inclusion criterion in 93 clinical trials for ovarian carcinoma, of which 58 are open and 35 are closed. Of the trials that contain HER2 status and ovarian carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 56 are phase 1 (28 open), 24 are phase 1/phase 2 (20 open), 11 are phase 2 (8 open), and 1 is phase 3 (1 open) [4].
Invasive Breast Carcinoma +
HER2 is an inclusion criterion in 80 clinical trials for invasive breast carcinoma, of which 73 are open and 7 are closed. Of the trials that contain HER2 status and invasive breast carcinoma as inclusion criteria, 3 are early phase 1 (3 open), 10 are phase 1 (8 open), 3 are phase 1/phase 2 (1 open), 47 are phase 2 (44 open), 1 is phase 2/phase 3 (1 open), 15 are phase 3 (15 open), and 1 is no phase specified (1 open) [4].
Breast Adenocarcinoma +
HER2 is an inclusion criterion in 58 clinical trials for breast adenocarcinoma, of which 54 are open and 4 are closed. Of the trials that contain HER2 status and breast adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 14 are phase 1 (14 open), 5 are phase 1/phase 2 (4 open), 20 are phase 2 (18 open), 14 are phase 3 (13 open), and 4 are no phase specified (4 open) [4].
Head And Neck Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 58 clinical trials for head and neck squamous cell carcinoma, of which 40 are open and 18 are closed. Of the trials that contain HER2 status and head and neck squamous cell carcinoma as inclusion criteria, 35 are phase 1 (23 open), 17 are phase 1/phase 2 (13 open), 5 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].
Melanoma +
HER2 is an inclusion criterion in 50 clinical trials for melanoma, of which 31 are open and 19 are closed. Of the trials that contain HER2 status and melanoma as inclusion criteria, 1 is early phase 1 (0 open), 26 are phase 1 (15 open), 9 are phase 1/phase 2 (7 open), 13 are phase 2 (8 open), and 1 is phase 3 (1 open) [4].
Endometrial Carcinoma +
HER2 is an inclusion criterion in 41 clinical trials for endometrial carcinoma, of which 34 are open and 7 are closed. Of the trials that contain HER2 status and endometrial carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 20 are phase 1 (17 open), 14 are phase 1/phase 2 (10 open), and 6 are phase 2 (6 open) [4].
Urothelial Carcinoma +
HER2 is an inclusion criterion in 41 clinical trials for urothelial carcinoma, of which 30 are open and 11 are closed. Of the trials that contain HER2 status and urothelial carcinoma as inclusion criteria, 20 are phase 1 (12 open), 15 are phase 1/phase 2 (12 open), and 6 are phase 2 (6 open) [4].
Renal Cell Carcinoma +
HER2 is an inclusion criterion in 38 clinical trials for renal cell carcinoma, of which 24 are open and 14 are closed. Of the trials that contain HER2 status and renal cell carcinoma as inclusion criteria, 21 are phase 1 (10 open), 10 are phase 1/phase 2 (8 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [4].
Fallopian Tube Carcinoma +
HER2 is an inclusion criterion in 37 clinical trials for fallopian tube carcinoma, of which 23 are open and 14 are closed. Of the trials that contain HER2 status and fallopian tube carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 25 are phase 1 (13 open), 7 are phase 1/phase 2 (6 open), 3 are phase 2 (2 open), and 1 is phase 4 (1 open) [4].
Pancreatic Carcinoma +
HER2 is an inclusion criterion in 37 clinical trials for pancreatic carcinoma, of which 27 are open and 10 are closed. Of the trials that contain HER2 status and pancreatic carcinoma as inclusion criteria, 20 are phase 1 (12 open), 11 are phase 1/phase 2 (9 open), and 6 are phase 2 (6 open) [4].
Small Cell Lung Carcinoma +
HER2 is an inclusion criterion in 36 clinical trials for small cell lung carcinoma, of which 27 are open and 9 are closed. Of the trials that contain HER2 status and small cell lung carcinoma as inclusion criteria, 17 are phase 1 (11 open), 14 are phase 1/phase 2 (11 open), and 5 are phase 2 (5 open) [4].
Primary Peritoneal Carcinoma +
HER2 is an inclusion criterion in 35 clinical trials for primary peritoneal carcinoma, of which 21 are open and 14 are closed. Of the trials that contain HER2 status and primary peritoneal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 23 are phase 1 (11 open), 7 are phase 1/phase 2 (6 open), 3 are phase 2 (2 open), and 1 is phase 4 (1 open) [4].
Cervical Carcinoma +
HER2 is an inclusion criterion in 32 clinical trials for cervical carcinoma, of which 27 are open and 5 are closed. Of the trials that contain HER2 status and cervical carcinoma as inclusion criteria, 20 are phase 1 (16 open), 7 are phase 1/phase 2 (6 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open) [4].
Prostate Carcinoma +
HER2 is an inclusion criterion in 31 clinical trials for prostate carcinoma, of which 20 are open and 11 are closed. Of the trials that contain HER2 status and prostate carcinoma as inclusion criteria, 19 are phase 1 (10 open), 8 are phase 1/phase 2 (7 open), and 4 are phase 2 (3 open) [4].
Bladder Carcinoma +
HER2 is an inclusion criterion in 27 clinical trials for bladder carcinoma, of which 17 are open and 10 are closed. Of the trials that contain HER2 status and bladder carcinoma as inclusion criteria, 16 are phase 1 (7 open), 3 are phase 1/phase 2 (3 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].
Hepatocellular Carcinoma +
HER2 is an inclusion criterion in 26 clinical trials for hepatocellular carcinoma, of which 21 are open and 5 are closed. Of the trials that contain HER2 status and hepatocellular carcinoma as inclusion criteria, 14 are phase 1 (10 open), 9 are phase 1/phase 2 (8 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].
Esophageal Adenocarcinoma +
HER2 is an inclusion criterion in 17 clinical trials for esophageal adenocarcinoma, of which 17 are open and 0 are closed. Of the trials that contain HER2 status and esophageal adenocarcinoma as inclusion criteria, 5 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 7 are phase 2 (7 open), and 2 are phase 3 (2 open) [4].
Pancreatic Adenocarcinoma +
HER2 is an inclusion criterion in 16 clinical trials for pancreatic adenocarcinoma, of which 10 are open and 6 are closed. Of the trials that contain HER2 status and pancreatic adenocarcinoma as inclusion criteria, 10 are phase 1 (7 open), 5 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].
Head And Neck Carcinoma +
HER2 is an inclusion criterion in 14 clinical trials for head and neck carcinoma, of which 9 are open and 5 are closed. Of the trials that contain HER2 status and head and neck carcinoma as inclusion criteria, 10 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].
Soft Tissue Sarcoma +
HER2 is an inclusion criterion in 14 clinical trials for soft tissue sarcoma, of which 8 are open and 6 are closed. Of the trials that contain HER2 status and soft tissue sarcoma as inclusion criteria, 8 are phase 1 (2 open), 5 are phase 1/phase 2 (5 open), and 1 is phase 2 (1 open) [4].
Lymphoma +
HER2 is an inclusion criterion in 13 clinical trials for lymphoma, of which 6 are open and 7 are closed. Of the trials that contain HER2 status and lymphoma as inclusion criteria, 9 are phase 1 (4 open) and 4 are phase 1/phase 2 (2 open) [4].
Ductal Carcinoma In Situ +
HER2 is an inclusion criterion in 12 clinical trials for ductal carcinoma in situ, of which 9 are open and 3 are closed. Of the trials that contain HER2 status and ductal carcinoma in situ as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 3 are phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 2 are no phase specified (2 open) [4].
Squamous Cell Lung Carcinoma +
HER2 is an inclusion criterion in 12 clinical trials for squamous cell lung carcinoma, of which 9 are open and 3 are closed. Of the trials that contain HER2 status and squamous cell lung carcinoma as inclusion criteria, 7 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].
Breast Invasive Ductal Carcinoma +
HER2 is an inclusion criterion in 11 clinical trials for breast invasive ductal carcinoma, of which 10 are open and 1 is closed. Of the trials that contain HER2 status and breast invasive ductal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), 2 are phase 3 (2 open), and 4 are no phase specified (3 open) [4].
Colorectal Adenocarcinoma +
HER2 is an inclusion criterion in 11 clinical trials for colorectal adenocarcinoma, of which 8 are open and 3 are closed. Of the trials that contain HER2 status and colorectal adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open), 4 are phase 1/phase 2 (3 open), and 4 are phase 2 (2 open) [4].
Glioblastoma +
HER2 is an inclusion criterion in 10 clinical trials for glioblastoma, of which 6 are open and 4 are closed. Of the trials that contain HER2 status and glioblastoma as inclusion criteria, 7 are phase 1 (5 open), 2 are phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].
Inflammatory Breast Carcinoma +
HER2 is an inclusion criterion in 10 clinical trials for inflammatory breast carcinoma, of which 9 are open and 1 is closed. Of the trials that contain HER2 status and inflammatory breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (1 open) [4].
Pancreatic Ductal Adenocarcinoma +
HER2 is an inclusion criterion in 10 clinical trials for pancreatic ductal adenocarcinoma, of which 6 are open and 4 are closed. Of the trials that contain HER2 status and pancreatic ductal adenocarcinoma as inclusion criteria, 7 are phase 1 (6 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (0 open) [4].
Prostate Adenocarcinoma +
HER2 is an inclusion criterion in 10 clinical trials for prostate adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain HER2 status and prostate adenocarcinoma as inclusion criteria, 5 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [4].
Mesothelioma +
HER2 is an inclusion criterion in 9 clinical trials for mesothelioma, of which 6 are open and 3 are closed. Of the trials that contain HER2 status and mesothelioma as inclusion criteria, 9 are phase 1 (6 open) [4].
Sarcoma +
HER2 is an inclusion criterion in 9 clinical trials for sarcoma, of which 6 are open and 3 are closed. Of the trials that contain HER2 status and sarcoma as inclusion criteria, 6 are phase 1 (4 open) and 3 are phase 1/phase 2 (2 open) [4].
Cholangiocarcinoma +
HER2 is an inclusion criterion in 8 clinical trials for cholangiocarcinoma, of which 6 are open and 2 are closed. Of the trials that contain HER2 status and cholangiocarcinoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Esophageal Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 8 clinical trials for esophageal squamous cell carcinoma, of which 8 are open and 0 are closed. Of the trials that contain HER2 status and esophageal squamous cell carcinoma as inclusion criteria, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].
High Grade Ovarian Serous Adenocarcinoma +
HER2 is an inclusion criterion in 8 clinical trials for high grade ovarian serous adenocarcinoma, of which 7 are open and 1 is closed. Of the trials that contain HER2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 7 are phase 1 (6 open) and 1 is phase 1/phase 2 (1 open) [4].
Merkel Cell Carcinoma +
HER2 is an inclusion criterion in 8 clinical trials for Merkel cell carcinoma, of which 7 are open and 1 is closed. Of the trials that contain HER2 status and Merkel cell carcinoma as inclusion criteria, 2 are phase 1 (1 open), 4 are phase 1/phase 2 (4 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Non-Squamous Non-Small Cell Lung Carcinoma +
HER2 is an inclusion criterion in 8 clinical trials for non-squamous non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain HER2 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].
Biliary Tract Carcinoma +
HER2 is an inclusion criterion in 7 clinical trials for biliary tract carcinoma, of which 7 are open and 0 are closed. Of the trials that contain HER2 status and biliary tract carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].
Cancer +
HER2 is an inclusion criterion in 7 clinical trials for cancer, of which 3 are open and 4 are closed. Of the trials that contain HER2 status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 3 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].
Clear Cell Renal Cell Carcinoma +
HER2 is an inclusion criterion in 6 clinical trials for clear cell renal cell carcinoma, of which 4 are open and 2 are closed. Of the trials that contain HER2 status and clear cell renal cell carcinoma as inclusion criteria, 5 are phase 1 (3 open) and 1 is phase 2 (1 open) [4].
Esophagogastric Carcinoma +
HER2 is an inclusion criterion in 6 clinical trials for esophagogastric carcinoma, of which 5 are open and 1 is closed. Of the trials that contain HER2 status and esophagogastric carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [4].
Gallbladder Carcinoma +
HER2 is an inclusion criterion in 6 clinical trials for gallbladder carcinoma, of which 6 are open and 0 are closed. Of the trials that contain HER2 status and gallbladder carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].
Malignant Ovarian Epithelial Tumor +
HER2 is an inclusion criterion in 6 clinical trials for malignant ovarian epithelial tumor, of which 6 are open and 0 are closed. Of the trials that contain HER2 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].
Nasopharyngeal Carcinoma +
HER2 is an inclusion criterion in 6 clinical trials for nasopharyngeal carcinoma, of which 5 are open and 1 is closed. Of the trials that contain HER2 status and nasopharyngeal carcinoma as inclusion criteria, 5 are phase 1 (4 open) and 1 is phase 1/phase 2 (1 open) [4].
Non-Hodgkin Lymphoma +
HER2 is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain HER2 status and non-hodgkin lymphoma as inclusion criteria, 6 are phase 1 (6 open) [4].
Skin Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 6 clinical trials for skin squamous cell carcinoma, of which 6 are open and 0 are closed. Of the trials that contain HER2 status and skin squamous cell carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 3 are phase 1/phase 2 (3 open) [4].
Acute Myeloid Leukemia +
HER2 is an inclusion criterion in 5 clinical trials for acute myeloid leukemia, of which 4 are open and 1 is closed. Of the trials that contain HER2 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (2 open) [4].
Lung Adenocarcinoma +
HER2 is an inclusion criterion in 5 clinical trials for lung adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain HER2 status and lung adenocarcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Malignant Uterine Neoplasm +
HER2 is an inclusion criterion in 5 clinical trials for malignant uterine neoplasm, of which 5 are open and 0 are closed. Of the trials that contain HER2 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].
Peritoneal Mesothelioma +
HER2 is an inclusion criterion in 5 clinical trials for peritoneal mesothelioma, of which 2 are open and 3 are closed. Of the trials that contain HER2 status and peritoneal mesothelioma as inclusion criteria, 4 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Carcinoma +
HER2 is an inclusion criterion in 4 clinical trials for carcinoma, of which 3 are open and 1 is closed. Of the trials that contain HER2 status and carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (1 open) [4].
Chronic Lymphocytic Leukemia +
HER2 is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 2 are closed. Of the trials that contain HER2 status and chronic lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].
Cutaneous Melanoma +
HER2 is an inclusion criterion in 4 clinical trials for cutaneous melanoma, of which 4 are open and 0 are closed. Of the trials that contain HER2 status and cutaneous melanoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Diffuse Large B-Cell Lymphoma +
HER2 is an inclusion criterion in 4 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 2 are closed. Of the trials that contain HER2 status and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Multiple Myeloma +
HER2 is an inclusion criterion in 4 clinical trials for multiple myeloma, of which 3 are open and 1 is closed. Of the trials that contain HER2 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [4].
Oropharyngeal Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 4 clinical trials for oropharyngeal squamous cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain HER2 status and oropharyngeal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Adenoid Cystic Carcinoma +
HER2 is an inclusion criterion in 3 clinical trials for adenoid cystic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HER2 status and adenoid cystic carcinoma as inclusion criteria, 3 are phase 1 (2 open) [4].
Bilateral Breast Carcinoma +
HER2 is an inclusion criterion in 3 clinical trials for bilateral breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HER2 status and bilateral breast carcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].
Bile Duct Carcinoma +
HER2 is an inclusion criterion in 3 clinical trials for bile duct carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HER2 status and bile duct carcinoma as inclusion criteria, 3 are phase 2 (2 open) [4].
Breast Lobular Carcinoma In Situ +
HER2 is an inclusion criterion in 3 clinical trials for breast lobular carcinoma in situ, of which 3 are open and 0 are closed. Of the trials that contain HER2 status and breast lobular carcinoma in situ as inclusion criteria, 2 are phase 2 (2 open) and 1 is no phase specified (1 open) [4].
Colon Carcinoma +
HER2 is an inclusion criterion in 3 clinical trials for colon carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HER2 status and colon carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].
High Grade Fallopian Tube Serous Adenocarcinoma +
HER2 is an inclusion criterion in 3 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain HER2 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Hypopharyngeal Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 3 clinical trials for hypopharyngeal squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HER2 status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].
Intrahepatic Cholangiocarcinoma +
HER2 is an inclusion criterion in 3 clinical trials for intrahepatic cholangiocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain HER2 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Laryngeal Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 3 clinical trials for laryngeal squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HER2 status and laryngeal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].
Malignant Pleural Mesothelioma +
HER2 is an inclusion criterion in 3 clinical trials for malignant pleural mesothelioma, of which 3 are open and 0 are closed. Of the trials that contain HER2 status and malignant pleural mesothelioma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].
Mantle Cell Lymphoma +
HER2 is an inclusion criterion in 3 clinical trials for mantle cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain HER2 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].
Pleural Mesothelioma +
HER2 is an inclusion criterion in 3 clinical trials for pleural mesothelioma, of which 0 are open and 3 are closed. Of the trials that contain HER2 status and pleural mesothelioma as inclusion criteria, 3 are phase 1 (0 open) [4].
Thymic Carcinoma +
HER2 is an inclusion criterion in 3 clinical trials for thymic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HER2 status and thymic carcinoma as inclusion criteria, 3 are phase 1 (3 open) [4].
Acute Lymphoblastic Leukemia +
HER2 is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain HER2 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].
Anal Canal Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for anal canal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Anal Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for anal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and anal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [4].
Anaplastic Astrocytoma +
HER2 is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain HER2 status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [4].
B-Cell Non-Hodgkin Lymphoma +
HER2 is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].
Cervical Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for cervical squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and cervical squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Classical Hodgkin Lymphoma +
HER2 is an inclusion criterion in 2 clinical trials for classical hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Endometrial Endometrioid Adenocarcinoma +
HER2 is an inclusion criterion in 2 clinical trials for endometrial endometrioid adenocarcinoma, of which 0 are open and 2 are closed. Of the trials that contain HER2 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (0 open) [4].
Endometrial Serous Adenocarcinoma +
HER2 is an inclusion criterion in 2 clinical trials for endometrial serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and endometrial serous adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Extrahepatic Cholangiocarcinoma +
HER2 is an inclusion criterion in 2 clinical trials for extrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and extrahepatic cholangiocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Fallopian Tube Endometrioid Adenocarcinoma +
HER2 is an inclusion criterion in 2 clinical trials for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain HER2 status and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].
Gastrointestinal Stromal Tumor +
HER2 is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 1 is open and 1 is closed. Of the trials that contain HER2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].
Hematopoietic And Lymphoid Malignancy +
HER2 is an inclusion criterion in 2 clinical trials for hematopoietic and lymphoid malignancy, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Leukemia +
HER2 is an inclusion criterion in 2 clinical trials for leukemia, of which 1 is open and 1 is closed. Of the trials that contain HER2 status and leukemia as inclusion criteria, 2 are phase 1 (1 open) [4].
Lobular Breast Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for lobular breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and lobular breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Lung Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HER2 status and lung carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].
Malignant Glioma +
HER2 is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and malignant glioma as inclusion criteria, 2 are phase 1 (2 open) [4].
Malignant Ovarian Clear Cell Tumor +
HER2 is an inclusion criterion in 2 clinical trials for malignant ovarian clear cell tumor, of which 1 is open and 1 is closed. Of the trials that contain HER2 status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].
Medullary Breast Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for medullary breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and medullary breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Mixed Lobular And Ductal Breast Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for mixed lobular and ductal breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and mixed lobular and ductal breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Myelodysplastic Syndromes +
HER2 is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 1 is open and 1 is closed. Of the trials that contain HER2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].
Neuroendocrine Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for neuroendocrine carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HER2 status and neuroendocrine carcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].
Oral Cavity Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for oral cavity squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Osteosarcoma +
HER2 is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Ovarian Endometrioid Adenocarcinoma +
HER2 is an inclusion criterion in 2 clinical trials for ovarian endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain HER2 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].
Primary Peritoneal Serous Adenocarcinoma +
HER2 is an inclusion criterion in 2 clinical trials for primary peritoneal serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Salivary Gland Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for salivary gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and salivary gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Small Intestinal Adenocarcinoma +
HER2 is an inclusion criterion in 2 clinical trials for small intestinal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain HER2 status and small intestinal adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].
Thymoma +
HER2 is an inclusion criterion in 2 clinical trials for thymoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and thymoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Thyroid Gland Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Uterine Corpus Carcinosarcoma +
HER2 is an inclusion criterion in 2 clinical trials for uterine corpus carcinosarcoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Vulvar Carcinoma +
HER2 is an inclusion criterion in 2 clinical trials for vulvar carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HER2 status and vulvar carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Adnexal Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for adnexal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and adnexal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ampulla Of Vater Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Anal Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for anal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and anal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Appendix Adenocarcinoma +
HER2 is an inclusion criterion in 1 clinical trial for appendix adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and appendix adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +
HER2 is an inclusion criterion in 1 clinical trial for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
B-Cell Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for B-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and B-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Basal Cell Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for basal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and basal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Benign Breast Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for benign breast neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and benign breast neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Biliary Tract Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for biliary tract neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and biliary tract neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Bladder Urothelial Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Bronchogenic Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Central Nervous System Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Cervical Carcinosarcoma +
HER2 is an inclusion criterion in 1 clinical trial for cervical carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and cervical carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Chordoma +
HER2 is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and chordoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Digestive System Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for digestive system carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and digestive system carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Double-Hit Lymphoma +
HER2 is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and double-hit lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Endometrial Mixed Adenocarcinoma +
HER2 is an inclusion criterion in 1 clinical trial for endometrial mixed adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and endometrial mixed adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Ependymoma +
HER2 is an inclusion criterion in 1 clinical trial for ependymoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and ependymoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Epithelioid Sarcoma +
HER2 is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Fallopian Tube Clear Cell Adenocarcinoma +
HER2 is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Follicular Lymphoma +
HER2 is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Gastric Diffuse Adenocarcinoma +
HER2 is an inclusion criterion in 1 clinical trial for gastric diffuse adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and gastric diffuse adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Germ Cell Tumor +
HER2 is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [4].
Glioma +
HER2 is an inclusion criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Gliosarcoma +
HER2 is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Hypopharyngeal Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for hypopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and hypopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Invasive Papillary Breast Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for invasive papillary breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and invasive papillary breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Kaposi Sarcoma +
HER2 is an inclusion criterion in 1 clinical trial for Kaposi sarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and Kaposi sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Kidney Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for kidney carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and kidney carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Laryngeal Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for laryngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and laryngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Leiomyosarcoma +
HER2 is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and leiomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Liposarcoma +
HER2 is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Low Grade Glioma +
HER2 is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Bone Marrow Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for malignant bone marrow neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and malignant bone marrow neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Central Nervous System Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Colorectal Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for malignant colorectal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and malignant colorectal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Digestive System Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for malignant digestive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and malignant digestive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Endometrial Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for malignant endometrial neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and malignant endometrial neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Exocrine Pancreatic Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for malignant exocrine pancreatic neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and malignant exocrine pancreatic neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Mixed Mesodermal (Mullerian) Tumor +
HER2 is an inclusion criterion in 1 clinical trial for malignant mixed mesodermal (mullerian) tumor, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and malignant mixed mesodermal (mullerian) tumor as inclusion criteria, 1 is early phase 1 (1 open) [4].
Malignant Ovarian Endometrioid Tumor +
HER2 is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].
Malignant Ovarian Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for malignant ovarian neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and malignant ovarian neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Thyroid Gland Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Malignant Urethral Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for malignant urethral neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and malignant urethral neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Uterine Corpus Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for malignant uterine corpus neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and malignant uterine corpus neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Medulloblastoma +
HER2 is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and medulloblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Metastatic Malignant Neoplasm In The Brain +
HER2 is an inclusion criterion in 1 clinical trial for metastatic malignant neoplasm in the brain, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and metastatic malignant neoplasm in the brain as inclusion criteria, 1 is phase 2 (0 open) [4].
Mucinous Breast Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for mucinous breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and mucinous breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Myxofibrosarcoma +
HER2 is an inclusion criterion in 1 clinical trial for myxofibrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and myxofibrosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
NUT Midline Carcinoma Of The Head And Neck +
HER2 is an inclusion criterion in 1 clinical trial for NUT midline carcinoma of the head and neck, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and NUT midline carcinoma of the head and neck as inclusion criteria, 1 is phase 1 (0 open) [4].
Non-Clear Cell Renal Cell Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Oral Cavity Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Oropharyngeal Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ovarian Carcinosarcoma +
HER2 is an inclusion criterion in 1 clinical trial for ovarian carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and ovarian carcinosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ovarian Endometrioid Tumor +
HER2 is an inclusion criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Ovarian Epithelial Tumor +
HER2 is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Pancreatic Neuroendocrine Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine neoplasm, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and pancreatic neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].
Papillary Renal Cell Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Penile Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and penile carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Peripheral T-Cell Lymphoma, Not Otherwise Specified +
HER2 is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].
Peritoneal Malignant Mesothelioma +
HER2 is an inclusion criterion in 1 clinical trial for peritoneal malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and peritoneal malignant mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Pleural Biphasic Mesothelioma +
HER2 is an inclusion criterion in 1 clinical trial for pleural biphasic mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and pleural biphasic mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Pleural Epithelioid Mesothelioma +
HER2 is an inclusion criterion in 1 clinical trial for pleural epithelioid mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and pleural epithelioid mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Pleural Mesothelioma, Sarcomatoid Type +
HER2 is an inclusion criterion in 1 clinical trial for pleural mesothelioma, sarcomatoid type, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and pleural mesothelioma, sarcomatoid type as inclusion criteria, 1 is phase 1 (1 open) [4].
Primary Peritoneal Carcinosarcoma +
HER2 is an inclusion criterion in 1 clinical trial for primary peritoneal carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and primary peritoneal carcinosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Prostate Undifferentiated Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for prostate undifferentiated carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and prostate undifferentiated carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Pseudomyxoma Peritonei +
HER2 is an inclusion criterion in 1 clinical trial for pseudomyxoma peritonei, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and pseudomyxoma peritonei as inclusion criteria, 1 is phase 1 (1 open) [4].
Renal Pelvis And Ureter Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for renal pelvis and ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and renal pelvis and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Rhabdoid Tumor +
HER2 is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].
Salivary Carcinoma, NOS +
HER2 is an inclusion criterion in 1 clinical trial for salivary carcinoma, NOS, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and salivary carcinoma, NOS as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Duct Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for salivary duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and salivary duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Acinic Cell Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for salivary gland acinic cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and salivary gland acinic cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Adenocarcinoma +
HER2 is an inclusion criterion in 1 clinical trial for salivary gland adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and salivary gland adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Carcinoma Ex Pleomorphic Adenoma +
HER2 is an inclusion criterion in 1 clinical trial for salivary gland carcinoma ex pleomorphic adenoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and salivary gland carcinoma ex pleomorphic adenoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Mucoepidermoid Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for salivary gland mucoepidermoid carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and salivary gland mucoepidermoid carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Small Cell Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for salivary gland small cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and salivary gland small cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Salivary Gland Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for salivary gland squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and salivary gland squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Sarcomatoid Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Small Intestinal Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for small intestinal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and small intestinal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Squamous Cell Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Squamous Cell Carcinoma Of The Penis +
HER2 is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 1 (1 open) [4].
Synovial Sarcoma +
HER2 is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
T-Cell And NK-Cell Neoplasm +
HER2 is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].
Tenosynovial Giant Cell Tumor +
HER2 is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and tenosynovial giant cell tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Tenosynovial Giant Cell Tumor, Diffuse Type +
HER2 is an inclusion criterion in 1 clinical trial for tenosynovial giant cell tumor, diffuse type, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and tenosynovial giant cell tumor, diffuse type as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid Gland Follicular Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HER2 status and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Transformed Non-Hodgkin Lymphoma +
HER2 is an inclusion criterion in 1 clinical trial for transformed non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Transitional Cell Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Tubular Breast Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for tubular breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and tubular breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ureter Urothelial Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Urethral Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for urethral carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and urethral carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Uterine Carcinosarcoma +
HER2 is an inclusion criterion in 1 clinical trial for uterine carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and uterine carcinosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Uveal Melanoma +
HER2 is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Vaginal Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and vaginal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Well-Differentiated Thyroid Gland Carcinoma +
HER2 is an inclusion criterion in 1 clinical trial for well-differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HER2 status and well-differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
